How soaring demand for Ozempic and Wegovy have led to Novo Nordisk's meteoric rise

Novo Nordisk has experienced astounding growth in the past few years with its new diabetes and obesity care drugs, Ozempic and Wegovy. Besides what they've done to transform the company's financials, the drugs also boast the potential to help solve the obesity crisis along with aiding in the treatment of cardiovascular diseases. Analysts say the drugs could be worth up to $300 billion annually in the near future.